ACCC | FDA Approves Blinatumomab for 72- and 96-Hour Infusion Durations
FDA Approves Blinatumomab for 72- and 96-Hour Infusion Durations
On December 17, the US Food and Drug Administration approved blinatumomab for 72- and 96-hour infusion durations to offer more flexibility for physicians and their patients.
